ThermoGenesis (THMO) 10-Q 11 Aug 22 2022 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 09, 2022
Document Information [Line Items]
Entity Central Index Key	0000811212
Entity Registrant Name	ThermoGenesis Holdings, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	333-82900
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3018487
Entity Address, Address Line One	2711 Citrus Road
Entity Address, City or Town	Rancho Cordova
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95742
City Area Code	916
Local Phone Number	858-5100
Title of 12(b) Security	Common Stock, $.001 par value
Trading Symbol	THMO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		31,321,362

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 4,001,000	$ 7,280,000
Accounts receivable, net of allowance for doubtful accounts of $156,000 at June 30, 2022 and December 31, 2021	2,309,000	733,000
Inventories	5,493,000	5,373,000
Prepaid expenses and other current assets	681,000	1,578,000
Total current assets	12,484,000	14,964,000
Inventories non-current, net	994,000	1,709,000
Equipment and leasehold improvements, net	1,279,000	1,261,000
Right-of-use operating lease assets, net	477,000	571,000
Goodwill	781,000	781,000
Other intangible assets, net	1,302,000	1,318,000
Other assets	256,000	48,000
Total assets	21,327,000	20,652,000
Current liabilities:
Accounts payable	1,240,000	1,280,000
Accrued payroll and related expenses	376,000	348,000
Deferred revenue – short-term	1,029,000	719,000
Convertible promissory note – related party	5,267,000
Interest payable – related party	709,000	2,231,000
Convertible promissory note, net	1,000,000	813,000
Other current liabilities	1,070,000	957,000
Total current liabilities	10,691,000	6,348,000
Convertible promissory note – related party, net		9,245,000
Operating lease obligations – long-term	274,000	398,000
Deferred revenue – long-term	1,095,000	1,244,000
Other noncurrent liabilities	18,000	20,000
Total liabilities	15,818,000	17,255,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding	0	0
Common stock, $0.001 par value; 350,000,000 shares authorized; 27,779,440 issued and outstanding (11,911,784 at December 31, 2021)	28,000	12,000
Additional paid in capital	265,596,000	268,447,000
Accumulated deficit	(259,521,000)	(264,662,000)
Accumulated other comprehensive loss	76,000	31,000
Total ThermoGenesis Holdings, Inc. stockholders’ equity	6,179,000	3,828,000
Noncontrolling interests	(670,000)	(431,000)
Total equity	5,509,000	3,397,000
Total liabilities and equity	21,327,000	$ 20,652,000
Lease Agreement with Z3 Investment LLC [Member]
Current assets:
Right-of-use operating lease assets, net	3,754,000
Current liabilities:
Operating lease obligations – long-term	$ 3,740,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Accounts receivable, allowance for doubtful accounts	$ 156,000	$ 156,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	27,779,440	11,911,784
Common stock, shares outstanding (in shares)	27,779,440	11,911,784

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net revenues	$ 3,029,000	$ 2,201,000	$ 5,692,000	$ 3,718,000
Cost of revenues	2,090,000	1,215,000	3,813,000	2,024,000
Gross profit	939,000	986,000	1,879,000	1,694,000
Expenses:
Selling, general and administrative	1,989,000	3,502,000	3,682,000	5,494,000
Research and development	392,000	622,000	847,000	1,001,000
Total operating expenses	2,381,000	4,124,000	4,529,000	6,495,000
Loss from operations	(1,442,000)	(3,138,000)	(2,650,000)	(4,801,000)
Other expenses:
Interest expense	(1,359,000)	(1,524,000)	(2,182,000)	(3,043,000)
Other income (expenses)		(10,000)	(4,000)	(11,000)
Gain on extinguishment of debt				(652,000)
Total other expense	(1,359,000)	(1,534,000)	(2,186,000)	(2,402,000)
Net loss	(2,801,000)	(4,672,000)	(4,836,000)	(7,203,000)
Loss attributable to noncontrolling interests	(113,000)	(133,000)	(239,000)	(251,000)
Net loss attributable to common stockholders	(2,688,000)	(4,539,000)	(4,597,000)	(6,952,000)
Net loss	(2,801,000)	(4,672,000)	(4,836,000)	(7,203,000)
Other comprehensive loss:
Foreign currency translation adjustments gain (loss)	31,000	12,000	45,000	13,000
Comprehensive loss	(2,770,000)	(4,660,000)	(4,791,000)	(7,190,000)
Comprehensive loss attributable to noncontrolling interests	(113,000)	(133,000)	(239,000)	(251,000)
Comprehensive loss attributable to common stockholders	$ (2,657,000)	$ (4,527,000)	$ (4,552,000)	$ (6,939,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (0.20)	$ (0.38)	$ (0.36)	$ (0.59)
Weighted average common shares outstanding – basic and diluted (in shares)	13,463,137	11,911,784	12,879,072	11,679,075

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Equity (Unaudited) - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member] Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	At The Market Offering Agreement [Member] Common Stock [Member]	At The Market Offering Agreement [Member] Additional Paid-in Capital [Member]	At The Market Offering Agreement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]		Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2020							8,934,952
Balance at Dec. 31, 2020							$ 9,000	$ 259,058,000	$ (253,283,000)	$ 16,000	[1]	$ 70,000	$ 5,870,000
Stock-based compensation expense								258,000					258,000
Issuance of common stock via at-the-market offering, net (in shares)							2,976,832
Issuance of common stock via at-the-market offering, net							$ 3,000	6,829,000					6,832,000
Foreign currency translation gain										1,000	[1]		1,000
Net loss									(2,413,000)			(118,000)	(2,531,000)
Balance (in shares) at Mar. 31, 2021							11,911,784
Balance at Mar. 31, 2021							$ 12,000	266,145,000	(255,696,000)	17,000	[1]	(48,000)	10,430,000
Balance (in shares) at Dec. 31, 2020							8,934,952
Balance at Dec. 31, 2020							$ 9,000	259,058,000	(253,283,000)	16,000	[1]	70,000	5,870,000
Foreign currency translation gain													13,000
Balance (in shares) at Jun. 30, 2021							11,911,784
Balance at Jun. 30, 2021							$ 12,000	268,244,000	(260,235,000)	29,000		(181,000)	7,869,000
Balance (in shares) at Mar. 31, 2021							11,911,784
Balance at Mar. 31, 2021							$ 12,000	266,145,000	(255,696,000)	17,000	[1]	(48,000)	10,430,000
Stock-based compensation expense								2,099,000					2,099,000
Foreign currency translation gain										12,000			12,000
Net loss									(4,539,000)			(133,000)	(4,672,000)
Balance (in shares) at Jun. 30, 2021							11,911,784
Balance at Jun. 30, 2021							$ 12,000	268,244,000	(260,235,000)	29,000		(181,000)	7,869,000
Balance (in shares) at Dec. 31, 2021							11,911,784
Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021	$ (10,681,000)	$ 9,739,000	$ (942,000)
Balance at Dec. 31, 2021							$ 12,000	268,447,000	(264,662,000)	31,000	[1]	(431,000)	3,397,000
Stock-based compensation expense								42,000					42,000
Issuance of common stock via at-the-market offering, net (in shares)				918,093
Issuance of common stock via at-the-market offering, net				$ 1,000	$ 593,000	$ 594,000
Related party convertible note price reset								213,000					213,000
Foreign currency translation gain										14,000	[1]		14,000
Net loss									(1,910,000)			(126,000)	(2,036,000)
Balance (in shares) at Mar. 31, 2022							12,829,877
Balance at Mar. 31, 2022							$ 13,000	258,614,000	(256,833,000)	45,000	[1]	(557,000)	1,282,000
Balance (in shares) at Dec. 31, 2021							11,911,784
Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021	$ (10,681,000)	$ 9,739,000	$ (942,000)
Balance at Dec. 31, 2021							$ 12,000	268,447,000	(264,662,000)	31,000	[1]	(431,000)	3,397,000
Issuance of common stock via at-the-market offering, net (in shares)						5,315,422
Related party convertible note price reset													2,688,000
Foreign currency translation gain													45,000
Balance (in shares) at Jun. 30, 2022							27,779,440
Balance at Jun. 30, 2022							$ 28,000	265,596,000	(259,521,000)	76,000		(670,000)	5,509,000
Balance (in shares) at Mar. 31, 2022							12,829,877
Balance at Mar. 31, 2022							$ 13,000	258,614,000	(256,833,000)	45,000	[1]	(557,000)	1,282,000
Stock-based compensation expense								72,000					72,000
Issuance of common stock via at-the-market offering, net (in shares)							4,397,329
Issuance of common stock via at-the-market offering, net							$ 4,000	1,446,000					1,450,000
Related party convertible note price reset								2,475,000					2,475,000
Foreign currency translation gain										31,000			31,000
Net loss									(2,688,000)			(113,000)	(2,801,000)
Conversion of related party note payable to common stock (in shares)							10,552,234
Conversion of related party note payable to common stock							$ 11,000	2,989,000					3,000,000
Balance (in shares) at Jun. 30, 2022							27,779,440
Balance at Jun. 30, 2022							$ 28,000	$ 265,596,000	$ (259,521,000)	$ 76,000		$ (670,000)	$ 5,509,000
[1]Accumulated other comprehensive loss.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (4,836,000)	$ (7,203,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	410,000	320,000
Stock based compensation expense	114,000	2,357,000
Amortization of Debt Discount (Premium)	955,000	1,815,000
Reserve for excess and slow-moving inventories	555,000	98,000
Gain on extinguishment of debt		(652,000)
Net change in operating assets and liabilities:
Accounts receivable	(1,576,000)	140,000
Inventories	37,000	(1,042,000)
Prepaid expenses and other assets	689,000	524,000
Accounts payable	1,000	(236,000)
Interest payable – related party	(1,522,000)	(976,000)
Accrued payroll and related expenses	28,000	(4,000)
Deferred revenue – short-term	310,000	294,000
Other current liabilities	119,000	(434,000)
Long-term deferred revenue and other noncurrent liabilities	(385,000)	(245,000)
Net cash used in operating activities	(5,101,000)	(5,244,000)
Cash flows from investing activities:
Capital expenditures	(219,000)	(80,000)
Net cash used in investing activities	(219,000)	(80,000)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of expenses	2,044,000	6,832,000
Net cash provided by financing activities	2,044,000	6,832,000
Effects of foreign currency rate changes on cash and cash equivalents	(3,000)	(1,000)
Net increase (decrease) in cash, cash equivalents and restricted cash	(3,279,000)	1,507,000
Cash, cash equivalents and restricted cash at beginning of period	7,280,000	7,161,000
Cash, cash equivalents and restricted cash at end of period	4,001,000	8,668,000
Supplemental disclosures of cash flow information:
Cash paid for related party interest	2,628,000	2,082,000
Cash paid for interest	120,000	$ 120,000
Right-to-use asset acquired under operating lease	3,863,000
Related party promissory note converted to common stock	3,000,000
Related party convertible note price reset	$ 2,688,000

Note 1 - Description of Busines

Note 1 - Description of Business	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”) develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. Since the 1990’s 1986 Medical Device Products for Automated Cell Processing The Company provides the AutoXpress® and BioArchive® platforms for automated clinical bio-banking, PXP® platform for point-of-care cell-based therapies and the CAR-TXpress™ platform for large scale cell manufacturing services. All product lines are reporting as a single reporting segment in the financial statements. Planned CDMO Business In March 2022, 2023.

Note 2 - Going Concern

Note 2 - Going Concern	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Going Concern The Company has incurred historical losses from operations and expects to continue to incur operating losses in the near future. The Company may may one The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The consolidated financial statements do not may

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	3. Summary of Significant Accounting Polices There have been no 2021 Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10 8 X. Operating results for the three six June 30, 2022 not may December 31, 2022. 10 December 31, 2021. Principles of Consolidation The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation. The 20% ownership interest of CARTXpress Bio that is not Recently Adopted Accounting Standards On January 1, 2022, 2020 06 Debt-Debt with Conversion and Other Options ( Subtopic 470 20 ) and Derivatives and Hedging-Contracts in Entity s Own Equity ( Subtopic 815 40 ): Accounting for Convertible Instruments and Contracts in an Entity s Own Equity, 2020 06 1 2 3 January 1, 2022 2022 $942,000.

Note 4 - Related Party Transact

Note 4 - Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	4. Related Party Transactions Convertible Promissory Note and Revolving Credit Agreement In March 2017, March 6, 2023 ( June 2022, June 30, 2022, The Credit Agreement and the Convertible Promissory Note issued thereunder (as amended, the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% per annum, simple interest. The Company has five The following summarizes the Note: Maturity Date Stated Interest Rate Conversion Price Face Value Debt Discount Carrying Value June 30, 2022 3/6/2023 22 % $ 0.28 $ 7,000,000 $ (1,733,000 ) $ 5,267,000 December 31, 2021 3/6/2022 22 % $ 1.80 $ 10,000,000 $ (755,000 ) $ 9,245,000 The Note includes a down-round anti-dilution provision that lowers its conversion price if the Company sells shares of common stock at a lower price per share. In February 2022, $213,000 Before After Conversion Price $ 1.80 $ 0.64 Term (in years) 0.02 0.02 Volatility 39.53 % 39.53 % Dividend rate 0 % 0 % Risk free rate 1.97 % 1.97 % In June 2022, Before After Conversion Price $ 0.64 $ 0.28 Term (in years) 0.69 0.69 Volatility 85.6 % 85.6 % Dividend rate 0 % 0 % Risk free rate 3.2 % 3.2 % The Company amortized $742,000 and $955,000 of debt discount to interest expense for the three six June 30, 2022. three June 30, 2022 June 2022. three six June 30, 2022 2021. June 30, 2022 December 31, 2021 Boyalife Genomics On March 24, 2022, Under the terms of the agreement, the Company transferred its remaining 8.64% interest in ImmuneCyte to Boyalife Genomics and agreed to pay a running royalty of 7.5% of its annual net sales of products and services that are covered by one three six June 30, 2022, no no

Note 5 - Related Party Lease

Note 5 - Related Party Lease	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	5. Related Party Lease Z3 On March 24, 2022, five Z3 April 1, 2022, first six two 5 1 The Company performed an analysis of the lease and determined it to be an operating lease. A right-of-use asset and lease obligation were recorded at the lease inception. Operating Lease Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not not The following summarizes the Company’s operating lease: June 30, 2022 Right-of-use operating lease assets – related party, net $ 3,754,000 Current lease liability (included in other current liabilities) 200,000 Non-current lease liability 3,740,000 Weighted average remaining lease term 5.3 Discount rate 22 % Maturities of lease liabilities by year for our operating lease are as follows: 2022 (Remaining) $ 449,000 2023 1,256,000 2024 1,307,000 2025 1,359,000 2026 1,428,000 Thereafter 1,133,000 Total lease payments $ 6,932,000 Less: imputed interest (2,992,000 ) Present value of operating lease liabilities $ 3,940,000 Statement of Cash Flows Cash paid for amounts included in the measurement of operating lease liabilities was $138,000 and $0 for the quarters ended June 30, 2022 2021,

Note 6 - Convertible Promissory

Note 6 - Convertible Promissory Note	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Convertible Promissory Note July 2019 On July 23, 2019, “July 2019 July 2019 July 2019 twenty-four July 2019 three July 31, 2022, July 2019 Subsequent to June 30, 2022, No. 2 July 2019 July 2019 January 31, 2023 January 31, 2023. The following summarizes the July 2019 Maturity Date Stated Interest Rate Conversion Price Carrying Value June 30, 2022 1/31/2023 24 % $ 0.50 $ 1,000,000 December 31, 2021 7/31/2022 24 % $ 0.91 $ 813,000 Amortization of debt discount on the July 2019 $0 three six June 30, 2022 three six June 30, 2021, July 2019 three six June 30, 2022 2021.

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	7. Stockholders Equity Common Stock On February 3, 2022, No. 2 may 2021 10 March 2022, 3. six June 30, 2022, Equity Plans On January 13, 2022, 2016 may Net Loss Per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents noted below is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at June 30: 2022 2021 Common stock equivalents of convertible promissory note and accrued interest 29,235,002 6,758,897 Warrants – other 653,248 653,248 Stock options 293,670 386,461 Total 30,181,920 7,798,606

Note 8 - Revenue

Note 8 - Revenue	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	8. Revenue The following table presents net sales by geographic areas: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 United States $ 1,573,000 $ 1,016,000 $ 3,439,000 $ 2,041,000 China 1,117,000 46,000 1,206,000 88,000 Thailand -- 398,000 7,000 400,000 Other 339,000 741,000 1,040,000 1,189,000 Total $ 3,029,000 $ 2,201,000 $ 5,692,000 $ 3,718,000 The following tables summarizes the revenues by product line and type: Three Months Ended June 30, 2022 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,923,000 $ 40,000 $ -- $ 1,963,000 BioArchive 338,000 305,000 -- 643,000 CAR-TXpress 163,000 58,000 71,000 292,000 Manual Disposables 102,000 -- -- 102,000 Other 23,000 -- 6,000 29,000 Total $ 2,549,000 $ 403,000 $ 77,000 $ 3,029,000 Six Months Ended June 30, 2022 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 3,634,000 $ 96,000 $ -- $ 3,730,000 BioArchive 493,000 603,000 -- 1,096,000 CAR-TXpress 361,000 101,000 142,000 604,000 Manual Disposables 207,000 -- -- 207,000 Other 40,000 -- 15,000 55,000 Total $ 4,735,000 $ 800,000 $ 157,000 $ 5,692,000 Three Months Ended June 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,048,000 $ 48,000 $ -- $ 1,096,000 BioArchive 223,000 326,000 -- 549,000 CAR-TXpress 287,000 30,000 72,000 389,000 Manual Disposables 116,000 -- -- 116,000 Other 30,000 -- 21,000 51,000 Total $ 1,704,000 $ 404,000 $ 93,000 $ 2,201,000 Six Months Ended June 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,273,000 $ 87,000 $ -- $ 1,360,000 BioArchive 431,000 868,000 -- 1,299,000 CAR-TXpress 542,000 58,000 143,000 743,000 Manual Disposables 245,000 -- -- 245,000 Other 37,000 -- 34,000 71,000 Total $ 2,528,000 $ 1,013,000 $ 177,000 $ 3,718,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three six June 30, 2022 June 30, 2022 December 31, 2021, June 30, 2022 December 31, 2021, Backlog of Remaining Customer Performance Obligations The following table represents revenue expected to be recognized in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period: Remainder of 2022 2023 2024 2025 2026 and beyond Total Service revenue $ 782,000 $ 682,000 $ 203,000 $ 83,000 $ -- $ 1,750,000 Device revenue (1) 41,000 733,000 41,000 -- -- 815,000 Exclusivity fee 143,000 286,000 286,000 286,000 191,000 1,192,000 Other 7,000 13,000 13,000 13,000 130,000 176,000 Total $ 973,000 $ 1,714,000 $ 543,000 $ 382,000 $ 321,000 $ 3,933,000 ( 1 Represents the minimum purchase requirements under the distribution agreement the Company signed with its AXP distributor in China.

Note 9 - Concentrations

Note 9 - Concentrations	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	9. The Company had certain customers whose revenue individually represented 10% 10% Accounts Receivable June 30, 2022 December 31, 2021 Customer 1 43 % -- Customer 2 12 % -- Customer 3 11 % -- Customer 4 9 % 23 % Customer 5 -- 23 % Revenues Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Customer 1 24 % 15 % 36 % 13 % Customer 2 32 % -- 17 % -- Customer 3 11 % 4 % 8 % 6 % Customer 4 -- 18 % -- 11 %

Note 10 - Subsequent Events

Note 10 - Subsequent Events	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	10. Subsequent Events Subsequent to June 30, 2022, On July 25, 2022, No. 2 July 2019 July 2019 January 31, 2023 January 31, 2023. July 28, 2022,

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10 8 X. Operating results for the three six June 30, 2022 not may December 31, 2022. 10 December 31, 2021.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation. The 20% ownership interest of CARTXpress Bio that is not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards On January 1, 2022, 2020 06 Debt-Debt with Conversion and Other Options ( Subtopic 470 20 ) and Derivatives and Hedging-Contracts in Entity s Own Equity ( Subtopic 815 40 ): Accounting for Convertible Instruments and Contracts in an Entity s Own Equity, 2020 06 1 2 3 January 1, 2022 2022 $942,000.

Note 4 - Related Party Transa_2

Note 4 - Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	Maturity Date Stated Interest Rate Conversion Price Face Value Debt Discount Carrying Value June 30, 2022 3/6/2023 22 % $ 0.28 $ 7,000,000 $ (1,733,000 ) $ 5,267,000 December 31, 2021 3/6/2022 22 % $ 1.80 $ 10,000,000 $ (755,000 ) $ 9,245,000
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Before After Conversion Price $ 1.80 $ 0.64 Term (in years) 0.02 0.02 Volatility 39.53 % 39.53 % Dividend rate 0 % 0 % Risk free rate 1.97 % 1.97 % Before After Conversion Price $ 0.64 $ 0.28 Term (in years) 0.69 0.69 Volatility 85.6 % 85.6 % Dividend rate 0 % 0 % Risk free rate 3.2 % 3.2 %

Note 5 - Related Party Lease (T

Note 5 - Related Party Lease (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Lease, Cost [Table Text Block]	June 30, 2022 Right-of-use operating lease assets – related party, net $ 3,754,000 Current lease liability (included in other current liabilities) 200,000 Non-current lease liability 3,740,000 Weighted average remaining lease term 5.3 Discount rate 22 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2022 (Remaining) $ 449,000 2023 1,256,000 2024 1,307,000 2025 1,359,000 2026 1,428,000 Thereafter 1,133,000 Total lease payments $ 6,932,000 Less: imputed interest (2,992,000 ) Present value of operating lease liabilities $ 3,940,000

Note 6 - Convertible Promisso_2

Note 6 - Convertible Promissory Note (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Convertible Debt [Table Text Block]	Maturity Date Stated Interest Rate Conversion Price Carrying Value June 30, 2022 1/31/2023 24 % $ 0.50 $ 1,000,000 December 31, 2021 7/31/2022 24 % $ 0.91 $ 813,000

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2022 2021 Common stock equivalents of convertible promissory note and accrued interest 29,235,002 6,758,897 Warrants – other 653,248 653,248 Stock options 293,670 386,461 Total 30,181,920 7,798,606

Note 8 - Revenue (Tables)

Note 8 - Revenue (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 United States $ 1,573,000 $ 1,016,000 $ 3,439,000 $ 2,041,000 China 1,117,000 46,000 1,206,000 88,000 Thailand -- 398,000 7,000 400,000 Other 339,000 741,000 1,040,000 1,189,000 Total $ 3,029,000 $ 2,201,000 $ 5,692,000 $ 3,718,000 Three Months Ended June 30, 2022 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,923,000 $ 40,000 $ -- $ 1,963,000 BioArchive 338,000 305,000 -- 643,000 CAR-TXpress 163,000 58,000 71,000 292,000 Manual Disposables 102,000 -- -- 102,000 Other 23,000 -- 6,000 29,000 Total $ 2,549,000 $ 403,000 $ 77,000 $ 3,029,000 Six Months Ended June 30, 2022 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 3,634,000 $ 96,000 $ -- $ 3,730,000 BioArchive 493,000 603,000 -- 1,096,000 CAR-TXpress 361,000 101,000 142,000 604,000 Manual Disposables 207,000 -- -- 207,000 Other 40,000 -- 15,000 55,000 Total $ 4,735,000 $ 800,000 $ 157,000 $ 5,692,000 Three Months Ended June 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,048,000 $ 48,000 $ -- $ 1,096,000 BioArchive 223,000 326,000 -- 549,000 CAR-TXpress 287,000 30,000 72,000 389,000 Manual Disposables 116,000 -- -- 116,000 Other 30,000 -- 21,000 51,000 Total $ 1,704,000 $ 404,000 $ 93,000 $ 2,201,000 Six Months Ended June 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,273,000 $ 87,000 $ -- $ 1,360,000 BioArchive 431,000 868,000 -- 1,299,000 CAR-TXpress 542,000 58,000 143,000 743,000 Manual Disposables 245,000 -- -- 245,000 Other 37,000 -- 34,000 71,000 Total $ 2,528,000 $ 1,013,000 $ 177,000 $ 3,718,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	Remainder of 2022 2023 2024 2025 2026 and beyond Total Service revenue $ 782,000 $ 682,000 $ 203,000 $ 83,000 $ -- $ 1,750,000 Device revenue (1) 41,000 733,000 41,000 -- -- 815,000 Exclusivity fee 143,000 286,000 286,000 286,000 191,000 1,192,000 Other 7,000 13,000 13,000 13,000 130,000 176,000 Total $ 973,000 $ 1,714,000 $ 543,000 $ 382,000 $ 321,000 $ 3,933,000

Note 9 - Concentrations (Tables

Note 9 - Concentrations (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	June 30, 2022 December 31, 2021 Customer 1 43 % -- Customer 2 12 % -- Customer 3 11 % -- Customer 4 9 % 23 % Customer 5 -- 23 % Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Customer 1 24 % 15 % 36 % 13 % Customer 2 32 % -- 17 % -- Customer 3 11 % 4 % 8 % 6 % Customer 4 -- 18 % -- 11 %

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Jun. 30, 2022	Mar. 31, 2022	Jan. 01, 2022	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance	$ 5,509,000	$ 1,282,000		$ 3,397,000	$ 7,869,000	$ 10,430,000	$ 5,870,000
Retained Earnings [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance	(259,521,000)	(256,833,000)		(264,662,000)	(260,235,000)	(255,696,000)	(253,283,000)
Additional Paid-in Capital [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance	$ 265,596,000	$ 258,614,000		268,447,000	$ 268,244,000	$ 266,145,000	$ 259,058,000
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2020-06 [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance				(942,000)
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2020-06 [Member] | Convertible Debt [Member]
Debt Instrument, Unamortized Discount, Total			$ (942,000)
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2020-06 [Member] | Retained Earnings [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance			9,739,000	9,739,000
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2020-06 [Member] | Additional Paid-in Capital [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance			$ (10,681,000)	$ (10,681,000)
CAR-TXpress [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	20%
Noncontrolling Interest, Ownership Percentage by Parent	80%

Note 4 - Related Party Transa_3

Note 4 - Related Party Transactions (Details Textual) - USD ($)		1 Months Ended	3 Months Ended				6 Months Ended
	Mar. 24, 2022	Jun. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Feb. 28, 2022	Dec. 31, 2021	Mar. 31, 2017
Amortization of Debt Discount (Premium)							$ 955,000	$ 1,815,000
Interest Paid, Excluding Capitalized Interest, Operating Activities							120,000	120,000
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total			$ 31,000	$ 14,000	$ 12,000	$ 1,000	45,000	13,000
ImmuneCyte [Member]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total	$ 8.64
Royalty, Percent of Annual Net Sales, US Patents	7.50%
Royalty, Percent of Annual Net Sales, Other Licensed Intellectual Property	5%
Convertible Note Converted into Common Stock [Member]
Debt Conversion, Original Debt, Amount		$ 3,000,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)		10,552,234
Boyalife Asset Holding II [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity											$ 10,000,000
Long-Term Line of Credit, Total		$ 7,000,000	$ 7,000,000				$ 7,000,000
Debt Instrument, Interest Rate, Stated Percentage		22%	22%				22%
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.28	$ 0.28				$ 0.28		$ 0.64
Debt Instrument, Unamortized Discount, Total		$ 2,475,000	$ 2,475,000				$ 2,475,000
Amortization of Debt Discount (Premium)			742,000				955,000
Interest Paid, Excluding Capitalized Interest, Operating Activities			556,000		$ 1,106,000		556,000	$ 1,106,000
Interest Payable		$ 709,000	$ 709,000				$ 709,000			$ 2,231,000

Note 4 - Related Party Transa_4

Note 4 - Related Party Transactions - Summarizes the Note (Details) - Boyalife Asset Holding II [Member] - Convertible Debt [Member] - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Maturity Date	Mar. 06, 2023	Mar. 06, 2023
Stated Interest Rate	22%	22%
Conversion Price (in dollars per share)	$ 0.28	$ 1.80
Face Value	$ 7,000,000	$ 10,000,000
Debt Discount	(1,733,000)	(755,000)
Carrying Value	$ 5,267,000	$ 9,245,000

Note 4 - Related Party Transa_5

Note 4 - Related Party Transactions - Black-Scholes Pricing Model (Details)	Jun. 30, 2022	May 31, 2022	Feb. 26, 2022	Feb. 25, 2022
Measurement Input, Conversion Price [Member]
Measurement input	0.28	0.64	0.64	1.80
Measurement Input, Expected Term [Member]
Measurement input	0.69	0.69	0.02	0.02
Measurement Input, Price Volatility [Member]
Measurement input	0.856	0.856	0.3953	0.3953
Measurement Input, Expected Dividend Rate [Member]
Measurement input	0	0	0	0
Measurement Input, Risk Free Interest Rate [Member]
Measurement input	0.032	0.032	0.0197	0.0197

Note 5 - Related Party Lease (D

Note 5 - Related Party Lease (Details Textual) - Lease Agreement with Z3 Investment LLC [Member]		3 Months Ended
	Mar. 24, 2022 USD ($) a	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)
Lessee, Operating Lease, Term of Contract (Year)	5 years
Area of Real Estate Property (Acre) | a	35,000
First Six Months, Rental Expense, Operating Leases	$ 46,000
Second Six Months, Rental Expense, Operating Lease	$ 104,000
Percent Increase, Annual Rental Expense	4%
Operating lease, Operating Expenses, Per Month	$ 5,000
Lessee, Operating Lease, Renewal Term (Year)	5 years
Operating Lease, Payments		$ 138,000	$ 0

Note 5 - Related Party Lease -

Note 5 - Related Party Lease - Lease Information (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Right-of-use operating lease assets – related party, net	$ 477,000	$ 571,000
Non-current lease liability	274,000	$ 398,000
Lease Agreement with Z3 Investment LLC [Member]
Right-of-use operating lease assets – related party, net	3,754,000
Non-current lease liability	$ 3,740,000
Weighted average remaining lease term (Year)	5 years 3 months 18 days
Discount rate	22%
Lease Agreement with Z3 Investment LLC [Member] | Current Liabilities [Member]
Current lease liability (included in other current liabilities)	$ 200,000

Note 5 - Related Party Lease _2

Note 5 - Related Party Lease - Maturities of Lease Liabilities (Details) - Lease Agreement with Z3 Investment LLC [Member]	Jun. 30, 2022 USD ($)
2022 (Remaining)	$ 449,000
2023	1,256,000
2024	1,307,000
2025	1,359,000
2026	1,428,000
Thereafter	1,133,000
Total lease payments	6,932,000
Less: imputed interest	(2,992,000)
Present value of operating lease liabilities	$ 3,940,000

Note 6 - Convertible Promisso_3

Note 6 - Convertible Promissory Note (Details Textual) - USD ($)		3 Months Ended		6 Months Ended
	Jul. 23, 2019	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jul. 25, 2022	Dec. 31, 2021
Amortization of Debt Discount (Premium)				$ 955,000	$ 1,815,000
Subsequent Event [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)						$ 0.21
Convertible Debt [Member] | The July 2019 Note [Member]
Debt Instrument, Face Amount	$ 1,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.50		$ 0.50			$ 0.91
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	90%
Debt Instrument, Interest Rate, Stated Percentage	24%	24%		24%			24%
Amortization of Debt Discount (Premium)		$ 0	$ 80,000	$ 0	161,000
Interest Expense, Debt, Total		$ 60,000	$ 120,000	$ 60,000	$ 120,000
Convertible Debt [Member] | The July 2019 Note [Member] | Subsequent Event [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)						$ 0.21
Convertible Debt [Member] | The July 2019 Note [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 1.80
Convertible Debt [Member] | The July 2019 Note [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.50

Note 6 - Convertible Promisso_4

Note 6 - Convertible Promissory Note - Convertible Promissory Note (Details) - Convertible Debt [Member] - The July 2019 Note [Member] - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Jul. 23, 2019
Stated Interest Rate	24%	24%	24%
Conversion Price (in dollars per share)	$ 0.50	$ 0.91
Carrying Value	$ 1,000,000	$ 813,000
Maturity Date	Jan. 31, 2023	Jul. 31, 2022

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual) - USD ($)		6 Months Ended
	Jan. 13, 2022	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022	Feb. 03, 2022
Proceeds from Issuance of Common Stock, Net		$ 2,044,000	$ 6,832,000
The 2016 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	392,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	1,200,000
At The Market Offering Agreement [Member]
Maximum Offering Price for Issuance of Common Stock				$ 18,573,000
Additional Common Stock, Shares Authorized					$ 4,275,000
Stock Issued During Period, Shares, New Issues (in shares)		5,315,422
Proceeds from Issuance of Common Stock		$ 2,255,000
Shares Issued, Average Price Per Share (in dollars per share)		$ 0.42
Proceeds from Issuance of Common Stock, Net		$ 2,044,000
Payments of Stock Issuance Costs		$ 211,000
At The Market Offering Agreement [Member] | Minimum [Member]
Maximum Offering Price for Issuance of Common Stock					15,280,000
At The Market Offering Agreement [Member] | Maximum [Member]
Maximum Offering Price for Issuance of Common Stock					$ 19,555,000

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Anti-dilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Anti-dilutive securities (in shares)	30,181,920	7,798,606
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)	29,235,002	6,758,897
Warrant, Other [Member]
Anti-dilutive securities (in shares)	653,248	653,248
Share-Based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)	293,670	386,461

Note 8 - Revenue (Details Textu

Note 8 - Revenue (Details Textual) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Contract with Customer, Liability, Revenue Recognized	$ 292,000	$ 641,000
Contract with Customer, Liability, Current	1,029,000	1,029,000	$ 719,000
Contract with Customer, Liability, Noncurrent	$ 1,095,000	$ 1,095,000	$ 1,244,000

Note 8 - Revenue - Revenues (De

Note 8 - Revenue - Revenues (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net revenues	$ 3,029,000	$ 2,201,000	$ 5,692,000	$ 3,718,000
Device [Member] | AXP [Member]
Net revenues	1,963,000	1,096,000	3,730,000	1,360,000
Device [Member] | BioArchive [Member]
Net revenues	643,000	549,000	1,096,000	1,299,000
Device [Member] | CAR-TXpress [Member]
Net revenues	292,000	389,000	604,000	743,000
Device [Member] | Manual Disposables [Member]
Net revenues	102,000	116,000	207,000	245,000
Device [Member] | Other Subsegments [Member]
Net revenues	29,000	51,000	55,000	71,000
Device Revenue [Member]
Net revenues	2,549,000	1,704,000	4,735,000	2,528,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Net revenues	1,923,000	1,048,000	3,634,000	1,273,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Net revenues	338,000	223,000	493,000	431,000
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	163,000	287,000	361,000	542,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Net revenues	102,000	116,000	207,000	245,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	23,000	30,000	40,000	37,000
Service [Member]
Net revenues	403,000	404,000	800,000	1,013,000
Service [Member] | Device [Member] | AXP [Member]
Net revenues	40,000	48,000	96,000	87,000
Service [Member] | Device [Member] | BioArchive [Member]
Net revenues	305,000	326,000	603,000	868,000
Service [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	58,000	30,000	101,000	58,000
Other [Member]
Net revenues	77,000	93,000	157,000	177,000
Other [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	71,000	72,000	142,000	143,000
Other [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	6,000	21,000	15,000	34,000
UNITED STATES
Net revenues	1,573,000	1,016,000	3,439,000	2,041,000
CHINA
Net revenues	1,117,000	46,000	1,206,000	88,000
THAILAND
Net revenues		398,000	7,000	400,000
All Other Countries [Member]
Net revenues	$ 339,000	$ 741,000	$ 1,040,000	$ 1,189,000

Note 8 - Revenue - Remaining Pe

Note 8 - Revenue - Remaining Performance Obligations (Details)	Jun. 30, 2022 USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 3,933,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	1,750,000
Device Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	815,000	[1]
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	1,192,000
Product and Service, Other [Member]
Revenue, Remaining Performance Obligation, Amount	$ 176,000
[1]Represents the minimum purchase requirements under the distribution agreement the Company signed with its AXP distributor in China.

Note 8 - Revenue - Remaining _2

Note 8 - Revenue - Remaining Performance Obligations 2 (Details)	Jun. 30, 2022 USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 3,933,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01
Revenue, Remaining Performance Obligation, Amount	$ 973,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Amount	$ 1,714,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Amount	$ 543,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Amount	$ 382,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Amount	$ 321,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Service [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,750,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01
Revenue, Remaining Performance Obligation, Amount	$ 782,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	9 months
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Amount	$ 682,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Amount	$ 203,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Amount	$ 83,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Device Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 815,000	[1]
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01
Revenue, Remaining Performance Obligation, Amount	$ 41,000	[1]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	9 months	[1]
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Amount	$ 733,000	[1]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year	[1]
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Amount	$ 41,000	[1]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year	[1]
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,192,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01
Revenue, Remaining Performance Obligation, Amount	$ 143,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	9 months
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Amount	$ 191,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Product and Service, Other [Member]
Revenue, Remaining Performance Obligation, Amount	$ 176,000
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01
Revenue, Remaining Performance Obligation, Amount	$ 7,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	9 months
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Amount	$ 130,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
[1]Represents the minimum purchase requirements under the distribution agreement the Company signed with its AXP distributor in China.

Note 9 - Concentrations - Accou

Note 9 - Concentrations - Accounts Receivables and Revenues (Details) - Customer Concentration Risk [Member]	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Accounts Receivable [Member] | Customer 1 [Member]
Concentration Risk, Percentage			43%
Accounts Receivable [Member] | Customer 2 [Member]
Concentration Risk, Percentage			12%
Accounts Receivable [Member] | Customer 3 [Member]
Concentration Risk, Percentage			11%
Accounts Receivable [Member] | Customer 4 [Member]
Concentration Risk, Percentage			9%		23%
Accounts Receivable [Member] | Customer 5 [Member]
Concentration Risk, Percentage					23%
Revenue from Contract with Customer Benchmark [Member] | Customer 1 [Member]
Concentration Risk, Percentage	24%	15%	36%	13%
Revenue from Contract with Customer Benchmark [Member] | Customer 2 [Member]
Concentration Risk, Percentage	32%		17%
Revenue from Contract with Customer Benchmark [Member] | Customer 3 [Member]
Concentration Risk, Percentage	11%	4%	8%	6%
Revenue from Contract with Customer Benchmark [Member] | Customer 4 [Member]
Concentration Risk, Percentage		18%		11%

Note 10 - Subsequent Events (De

Note 10 - Subsequent Events (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Aug. 01, 2022	Jun. 30, 2022	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Jul. 25, 2022
Stock Issued During Period, Value, New Issues		$ 1,450,000	$ 6,832,000
Proceeds from Issuance of Common Stock, Net				$ 2,044,000	$ 6,832,000
Subsequent Event [Member]
Stock Issued During Period, Value, New Issues	$ 3,541,922
Proceeds from Issuance of Common Stock	1,038,000
Proceeds from Issuance of Common Stock, Net	996,000
Payments of Stock Issuance Costs	$ 42,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)						$ 0.21